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Introduction
Despite epidemiological studies suggesting that heavy can­
nabis use during adolescence increases the risk for neuro­
psychiatric disorders later in life,1–3 cannabis remains the 
world’s most widely used illicit substance,4 especially among 
adolescents. It is therefore necessary to comprehend thor­
oughly the molecular underpinnings enhancing adolescent 
brain vulnerability to adverse effects from cannabis.
A growing body of literature on animal models has uncov­
ered a clear association between adolescent cannabinoid ex­
posure and the development of specific traits of psychiatric 
disorders.5–7 We have shown previously that chronic admin­
istration of Δ9­tetrahydrocannabinol (THC), the psychoactive 
ingredient of cannabis, in adolescent but not adult female rats 
induces behavioural and biochemical signs relevant for de­
pression and psychosis8–13 later in life. Interestingly, long­
term effects of THC seem to be sex­specific. In fact, adoles­
cent male rats exposed to the same THC treatment as females 
experienced only cognitive deficits.8,14 In view of the more 
complex phenotype in adolescent female rats exposed to 
THC, we decided to focus the present study on female rats.
In recent years, many studies have focused on the involve­
ment of epigenetic mechanisms in the causes and subsequent 
development of psychiatric illnesses, such as drug addiction 
and depression.15,16 However, hints on epigenetic effects of 
THC exposure are generally scarce, particularly regarding 
adolescent THC administration.17 Despite the limited evi­
dence, the few studies addressing this topic, although based 
on very different experimental models, suggest that THC 
may principally act on the epigenome through the modula­
tion of the repressive histone marker H3K9me3.18–23
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Background: Increasing cannabis consumption among adolescents, studies that link its early use with mental illnesses, and the political 
debate on cannabis legalization together call for an urgent need to study molecular underpinnings of adolescent brain vulnerability. The 
emerging role of epigenetic mechanisms in psychiatric diseases led us to hypothesize that epigenetic alterations could play a role in 
causes and subsequent development of the depressive/psychotic-like phenotype induced by adolescent, but not adult, Δ9-
tetrahydrocannabinol (THC) exposure in female rats. Methods: We performed a time-course analysis of histone modifications, chroma-
tin remodelling enzymes and gene expression in the prefrontal cortex of female rats after adolescent and adult THC exposure. We also 
administered a specific epigenetic drug (chaetocin) with THC to investigate its impact on THC-induced behavioural alterations. Results: 
Adolescent THC exposure induced alterations of selective histone modifications (mainly H3K9me3), impacting the expression of genes 
closely associated with synaptic plasticity. Changes in both histone modifications and gene expression were more widespread and in-
tense after adolescent treatment, suggesting specific adolescent susceptibility. Adolescent THC exposure significantly increased 
Suv39H1 levels, which could account for the enhanced H3K9me3. Pharmacological blockade of H3K9me3 during adolescent THC treat-
ment prevented THC-induced cognitive deficits, suggesting the relevant role played by H3K9me3 in THC-induced effects. Limitations: 
Only female rats were investigated, and the expression studies were limited to a specific subset of genes. Conclusion: Through a 
mechanism involving SUV39H1, THC modifies histone modifications and, thereby, expression of plasticity genes. This pathway appears 
to be relevant for the development of cognitive deficits.
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In the present study we investigated whether specific epi­
genetic mechanisms may contribute to the molecular events 
triggered by adolescent THC exposure and whether these 
modifications are different after adult THC exposure. We 
show that different histone H3 modifications — mainly in­
crease of H3K9me3 — occur in the prefrontal cortex (PFC) of 
female rats exposed to THC during adolescence. These 
 epigenetic alterations are translated into disease­relevant 
trans criptional changes involving a subset of genes closely 
associated with the endocannabinoid system (ECS) and 
neuro plasticity processes. Adulthood THC administration 
showed milder and short­lasting effects on the epigenome, 
reflecting minor changes on the transcriptional point of view. 
Administration of a specific epigenetic drug — inhibiting the 
main enzymes responsible for THC­induced H3K9me3 
 upregulation — restores cognitive THC­related issues. We 
propose that an epigenetic­driven molecular mechanism con­
tributes to adolescence­specific THC vulnerability, suggest­
ing a causal relationship between epigenome modification 
and cognitive deficits, a core sign of the complex depressive/ 
psychotic­like phenotype representing the adult consequence 
of THC exposure during adolescence.
Methods
Drugs and treatments
The THC was given to us by GW Pharmaceuticals; it was dis­
solved in ethanol, kolliphor and saline (1:1:18). We purchased 
the chaetocin from Cayman Chemical; it was dissolved in 
 dimethyl sulfoxide, polysorbate 80 and saline (1:1:8).
Female Sprague­Dawley rats received increasing intraperi­
toneal (IP) doses of THC twice a day (2.5, 5 and 10 mg/kg) or 
its vehicle, as previously described.8 In the adolescent setting, 
THC injections began at 35 postnatal days (PND) and lasted 
until 45 PND (Fig. 1A), whereas in the adult setting they 
started at 75 PND and lasted until 85 PND (Fig. 1B). This pro­
tocol mimics heavy Cannabis use according to the human­
equivalent dose proposed by the United States Food and 
Drug Administration and the average content of THC in a 
marijuana cigarette; our first dose roughly corresponded to 
1 marijuana cigarette containing 7% THC, the second dose 
corresponded to 2, and the higher dose corresponded to 
4 marijuana cigarettes.24 However, according to data coming 
from the United States and Europe, we now know that 
strains of cannabis with a THC content of up to 14% are also 
used. In this case, our treatment would mimic the consump­
tion of half (first dose), 1 (second dose) and 2 marijuana ciga­
rettes (third dose). This protocol was based on the observa­
tion that the adverse consequences of cannabis use are most 
evident among heavy users in early adolescence.25
For cotreatment, we administered chaetocin intraperiton­
eally at the dose of 0.05 mg/kg once a day during THC treat­
ment (Fig. 1C). No overt signs of toxicity were detected after 
chaetocin treatment. All experiments were performed accord­
ing to the guidelines for care and use of experimental animals 
in the European Communities Council directive (2010/63/
UE L 276 20/10/2010) and approved by the Ethical Commit­
tee for Animal Research at the University of Insubria and by 
the Italian Ministry of Health (Aut. N.302/2015­PR). All ef­
forts were made to reduce the suffering and the number of 
animals used.
Behavioural test
The rats were subjected to the novel object recognition 
(NOR), social interaction (SI) and forced swim tests (FST) as 
previously described.13 For detailed information, see Appen­
dix 1, available at jpn.ca/170082­a1. Behavioural data were 
expressed as means ± standard errors of the mean (SEM) and 
analyzed using 2­way analysis of variance (ANOVA) fol­
lowed by a Tukey multiple comparison post hoc test.
Molecular assays
We obtained PFC samples from the rats via regional dissection 
on ice. The tissue was immediately frozen in liquid nitrogen 
and stored at –80°C until processing. Nuclear protein and his­
tone extraction was performed as described in Appendix 1.
Western blot was performed as reported previously.12 For 
detailed information, see Appendix 1.
Total RNA was extracted from the PFC using the TRIzol 
protocol and incubated with DNase I to digest DNA contam­
ination for 10 minutes at 25°C (RNase­Free DNase set, Qia­
gen Sciences Inc.). After the digestion, the RNA was purified 
and concentrated according to the manufacturer’s manual 
using the RNeasy MinElute Cleanup kit (Qiagen). The RNA 
concentration was ensured spectrophotometrically. All RNA 
samples had A260:280 ratios of 1.8:2.0 after purification using 
an RNeasy MinElute Cleanup kit. We reverse­transcribed 
1 μg of total RNA from each sample into complementary 
DNA (cDNA) using an RT2 First Strand Kit (Qiagen) accord­
ing to the manufacturer’s protocol.
Gene profiling was done using the RT2 Profile PCR Array 
Custom Rat Synaptic Plasticity kit (Qiagen; see the complete 
list of genes in Appendix 1, Table S1). We designed the array 
using a 96­well format to simultaneously analyze the expres­
sion of 41 genes for each experimental group (control v. 
THC). The panel included genes associated with the ECS 
(Cnr1, Faah, Mgll, Ppara and Pparg), the glutamatergic and 
GABAergic system (Gria1, Gria2, Grin1, Grin2a, Grin2b, Grm1, 
Grm2, Grm3, Grm5, Gabbr1, Gabbr2, Gabra1,  Gabra2, Gabrb1, 
Gad1 and Abat) and the serotonergic system (Htr2a); the re­
modelling chromatin enzyme Sirt1; genes encoding proteins 
associated with plasticity (Bdnf, Dlg4, Ntrk12, Camk2a, 
Camk2g, Pdyn, Prkaca, Nos1, Creb1, Homer1, Pick1, Synpo, 
Crebbp, Arc, Reln and Adcy1); and housekeeping genes (Bact 
and Gapdh). In addition, 1 well contains a genomic DNA con­
trol, 3 wells contain reverse­transcription controls, and 
3 wells contain a positive polymerase chain reaction (PCR) 
control. The realtime PCR cycling program was run on a 
Chromo4 thermal cycler (Biorad).
Gene expression was normalized to Gapdh because it was 
more stable, and no significant changes were detected be­
tween the groups. The threshold and baseline were set manu­
ally according to the manufacturer’s instructions. Gene 
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 expression was calculated using the PCR Array Data Analy­
sis website (http://pcrdataanalysis.sabiosciences.com/pcr 
/arrayanalysis.php). Values were obtained for the threshold 
 cycle (Ct) for each gene, normalized using the Gapdh house­
keeping gene on the same array, and then transformed into 
base­2 logarithms. Faah and Pparg Ct values were too high 
(>  35) to be detectable with this approach. Differences be­
tween groups were assessed using a Student t test with 
Welch correction or 2­way ANOVA followed by a Tukey 
multiple comparison post hoc test. Data were analyzed using 
GraphPad Prism 4 software.
Chromatin immunoprecipitation was performed as re­
ported previously.26 The PFC was crosslinked in formalde­
hyde and underwent chromatin ultrasound fragmentation. 
For each sample, 40 mg of sonicated chromatin was immuno­
precipitated with H3K9me3 antibody (AbCam). Subse­
quently, phenol­chloroform precipitation of DNA was fol­
lowed by qualitative PCR analysis. To choose the specific 
Fig. 1: Δ9-Tetrahydrocannabinol (THC) treatment schedule in (A) adolescent and (B) adult female rats. (C) Protocol of chaetocin 
administration during adolescent THC treatment. i.p. = intraperitoneal; PND = postnatal day.
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target region to be analyzed by chromatin immunoprecipita­
tion we searched the ENCODE data for levels of H3K9 tri­
methylation in the UCSC Genome browser for every ana­
lyzed gene in the most comparable annotated tissue (i.e., 
mouse whole brain). According to the literature, H3K9me3­
enriched regions were mainly found in the gene bodies. Re­
garding Grin1, we designed primers encompassing the gen­
omic region, including the proximal promoter and the first 
part of the transcribed sequence. For all other genes (Abat, 
Mgll, Homer1 and Dlg4), we selected intronic and exonic re­
gions mapping in the gene bodies. Primer sequences are 
shown in Appendix 1, Table S2. The DNA enrichments are 
expressed over the input samples. We assessed differences 
between treated and control animals using a Student t test.
Results
Adolescent THC exposure impacts global histone modifications
To assess the effect of adolescent THC exposure on histone 
modifications in the rat PFC, we performed a time­course 
analysis of 5 different histone H3 modifications (Fig. 2A). We 
investigated markers associated with both transcriptional 
 repression (di­ and trimethylation of lysine 9 [H3K9me2 
and H3K9me3] as well as trimethylation of lysine 27 
[H3K27me3]) and transcriptional activation (acetylation of 
 lysine 9 [H3K9ac] and lysine 14 ]H3K14ac]) 2, 24 and 
48 hours after the last THC injection. Two hours after the last 
THC injection, H3K9me3 was significantly increased (25%). 
Fig. 2: (A) Effect of adolescent Δ9-tetrahydrocannabinol (THC) exposure on histone modifications 2, 24 and 48 hours after the last 
THC injection. Data are expressed as means ± standard errors of the mean (SEM) for at least 8 animals per experimental group. 
*p < 0.05 compared with controls (Student t test with Welch correction). (B) Effect of adolescent THC exposure on Suv39H1 levels 
2, 24 and 48 hours after the last THC injection. Data are expressed as means ± SEM for at least 6 animals per experimental group. 
*p < 0.05 compared with controls (Student t test with Welch correction). TBP = tata binding protein; VEH = vehicle.
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Twenty­four hours later, the increase of H3K9me3 was evi­
dent with even enhanced intensity (48%) together with a sig­
nificant increase of H3K9me2 (25%). Meanwhile, at 24 hours 
the positive histone mark H3K14ac started to increase (24%). 
Forty­eight hours after the last treatment, H3K9me3, 
H3K9me2 and H3K14ac returned to control values, whereas 
H3K9ac significantly increased (30%). This picture suggests 
that 2 waves of epigenetic modifications occur following 
chronic THC treatment, with the former (immediately after 
chronic THC exposure) being associated with transcriptional 
repression and the latter (at later time points) promoting a 
switch toward transcriptional activation.
Increased H3K9me3 levels represent the main effect in­
duced by adolescent THC exposure from 2 to 24 hours after 
the end of the treatment. The delayed increase (from 24 to 
48 hours after treatment) in acetylation of H3K9/14 residues 
could instead be interpreted as a homeostatic mechanism 
aimed at counterbalancing the strong repressional state ini­
tially induced by THC. Since the main histone methyltrans­
ferases (HMTs) responsible for lysine 9 methylation are 
Suv39H1 and G9a,27–30 we next asked whether THC exposure 
during adolescence could alter the expression of these en­
zymes. Adolescent THC treatment induced a significant in­
crease in Suv39H1 from 2 to 24 hours after the last injection, 
in the same time frame of H3K9me3 increase. Consistently, 
24 hours later, when H3K9me3 returned to control levels, 
Suv39H1 protein expression also underwent normalization 
(Fig. 2B). Levels of Suv39H1 were already enhanced during 
the adolescent THC treatment (PND 39; Appendix 1, 
Fig. S1A). In contrast, THC treatment did not induce any 
 alteration in G9a protein expression (Appendix 1, Fig. S1B).
Adolescent THC exposure alters gene expression
Because histone modifications impact transcriptional activity, 
we investigated the effect of adolescent THC exposure on 
gene expression. It is known that adolescence is characterized 
by intense processes of neuronal refinement,31 in which the 
ECS seems to play a crucial role.10 On this basis, we focussed 
our analyses on the expression of genes closely associated 
with the ECS and genes involved in plasticity processes. Two 
hours after the last THC injection statistical analysis revealed 
a significant decrease of Crebbp (–1.42 ± 0.13, n = 4, p < 0.01) 
and the immediate early gene Arc (–2.10 ± 0.44, n = 4, p < 
0.01) messenger RNA (mRNA) levels. Twenty­four hours 
 after the treatment (Fig. 3A), downregulation of THC­ induced 
gene expression became more evident. Of the 37 plasticity ­
related genes analyzed, 29 underwent significant downregu­
lation of mRNA levels. Alterations included genes belonging 
to the ECS (Cnr1 and Mgll), the glutamatergic system (Gria1, 
Gria2, Grin2a, Grin2b, Grm2, Grm3 and Grm5), the GABAergic 
system (Gabbr1, Gabbr2, Gabra2, Gad1 and Abat) and the sero­
tonergic system (Htr2a) and genes encoding proteins in­
volved in the modulation of neuronal plasticity (Bdnf, Dlg4, 
Sirt1, Pdyn, Prkaca, Nos1, Creb1, Homer1, Pick1, Synpo, Crebbp, 
Arc, Reln and Adcy1). This picture suggests that adolescent 
THC exposure induces significant transcriptional repression 
in this subset of plasticity genes. In contrast, 48 hours after 
the last THC injection (Fig. 3B) all the previously downregu­
lated mRNAs returned to control levels, and Gria2, Grm2, 
Gabbr1, Gad1 and Sirt1 expression significantly increased 
over control values.
To evaluate long­term alterations in gene expression in­
duced by adolescent THC exposure, we performed gene pro­
filing at 75 PND (Fig. 4), when the depressive/psychotic­like 
phenotype becomes evident. Seven genes, Gria1, Gria2, Grm3, 
Gabra1, Abat, Dlg4 and Ntrk12, showed upregulated mRNA 
levels, whereas only 1 gene, Reln, showed significantly down­
regulated mRNA. Reelin level variations are highly relevant 
in psychotic disorders,32 hence we also investigated Reelin 
protein expression upon THC exposure. We found decreased 
levels of Reelin isoforms 410 KDa and 180 KDa, whereas 
 Reelin 330 KDa was unchanged (Appendix 1, Fig. S2).
THC-induced modifications of gene expression are accompanied 
by inherent changes in chromatin structure
Because the major THC­dependent gene repression occurs 
24 hours after the end of chronic treatment, we investigated 
whether the observed global increase in H3K9me3 specif­
ically entailed chromatin changes in genes whose expression 
was modified by THC. We performed quantitative chromatin 
immunoprecipitation, selecting those genes displaying either 
stronger or highly significant modulation among all the 
THC­downregulated genes (Homer1, Mgll, Abat and Dlg4). In 
parallel we analyzed a gene, Grin1, whose expression was 
not modified after THC treatment. Analyzed genomic 
 regions were selected within the gene bodies. H3K9me3 is 
generally distributed at the level of coding sequences rather 
than peaking at proximal promoter regions.33 Interestingly, 
we detected a THC­ dependent increase of H3K9me3 levels in 
all the THC­ downregulated genes, except for Abat. With re­
gard to Grin1, whose expression was unaffected by the treat­
ment, no differences were observed in terms of H3K9me3 be­
tween THC­ and vehicle­treated rats (Fig. 5).
Adult v. adolescent THC exposure differentially affects 
 histone modifications and gene expression
Because the onset of the depressive/psychotic­like pheno­
type is restricted to adolescent THC exposure,8–14 we investi­
gated whether described alterations in histone modifications 
and gene expression were restricted to the adolescent treat­
ment. We performed the same protocol of injections (Fig. 1B), 
and the same histone modifications and gene expression 
analysis in adult female rats. Two hours after the last THC in­
jection, we observed a significant increase in H3K9me3 levels 
(54%) reminiscent to that of adolescent treatment. However, 
in contrast to the effects observed in adolescent rats, adult 
THC exposure did not lead to any significant alteration 24 
and 48 hours after the end of THC treatment (Fig. 6A). The 
most divergent profile of THC­induced histone modifications 
between rats treated in adolescence and rats treated in adult­
hood was observed 24 hours after the end of THC adminis­
tration, which is why we chose this time point to perform 
gene expression analysis in adult animals (Fig. 6B). Statistical 
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Fig. 3: Effect of adolescent Δ9-tetrahydrocannabinol (THC) exposure on the expression of genes closely associated 
with the endocannabinoid system or synaptic plasticity (A) 24 hours and (B) 48 hours after the last THC injection. Data 
are expressed as log2 ± standard errors of the mean for at least 4 animals per experimental group.  *p < 0.05, **p < 
0.01, ***p < 0.001 (Student t test with Welch correction). VEH = vehicle. 
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analysis showed that only a few genes (Ppara, Grm2, Pick1, 
and Reln) were significantly downregulated in the PFC of 
adult THC–treated animals. Interestingly, Bdnf gene expres­
sion was significantly increased only in THC­treated adult 
rats. These data suggest that transcriptional repression in­
duced by adult THC exposure was less intense and wide­
spread than that induced by adolescent THC exposure.
Chaetocin-induced H3K9me3 inhibition during adolescent 
THC exposure prevents downregulation of gene expression 
and adult cognitive deficits
To investigate the possible role of H3K9me3 increase induced 
by adolescent THC exposure,8–13 we administered chaetocin, 
an inhibitor of the HMTs SUV39H1 and G9a,34,35 simultane­
ously with THC treatment. To establish the active dose of 
chaetocin in vivo, we first tested 2 different intraperitoneal 
doses (0.05 mg/kg and 0.1 mg/kg), and 24 hours after the in­
jection, we investigated H3K9me3 levels. Only the 0.05 mg/kg 
dose of chaetocin significantly decreased H3K9me3 
(Appendix 1, Fig. S3A). Further studies are needed to under­
stand the reason why the higher chaetocin dosage was not ef­
fective in modulating SUV39H1 and, therefore, its specific 
target histone marker. Thus, we administered the 0.05 mg/kg 
dose once a day during the adolescent THC treatment. 
Twenty­four hours after the end of the treatment, we checked 
its effect on H3K9me3. As expected, THC induced a signifi­
cant increase in H3K9me3 levels (p < 0.05), and chaetocin co­
administration prevented such an increase (Appendix 1, 
Fig. S3B). Regarding gene expression, chaetocin coadminis­
tration prevented most of the THC­induced downregulation 
observed 24 hours after the end of the treatment. In fact, 
downregulation of 19 of 29 genes was prevented by chaeto­
cin coadministration (Table 1), whereas the decrease of 
10 mRNAs was not recovered by this cotreatment (Table 2).
Finally, to investigate the effect of H3K9me3 inhibition on 
the development of the depressive/psychotic­like phenotype, 
adult animals (PND 75) that had been pre­exposed to THC 
and chaetocin during adolescence were submitted to a battery 
of behavioural tests. In the NOR test, 2­way ANOVA showed 
a significant effect of THC treatment (F1–32 = 38.52, p < 0.001) as 
well as a significant effect of chaetocin (F1–32 = 63.63, p < 0.001) 
and a significant THC × chaetocin interaction (F1–32 = 84.68, p < 
0.001). In fact, as expected, adult rats pre­ exposed to THC 
showed a lower discrimination index (DI) than controls (p < 
0.001); the DI did not differ between controls and rats co­
treated with THC and chaetocin (Fig. 7A). There were no dif­
ferences in total exploration time between experimental 
Fig. 4: Effect of adolescent Δ9-tetrahydrocannabinol (THC) exposure on the expression of genes closely associated 
with the endocannabinoid system or synaptic plasticity at 75 postnatal days. Data are expressed as log2 ± standard 
errors of the mean for 8 animals per experimental group. *p < 0.05, **p < 0.01, ***p < 0.001 compared with controls 
(Student t test with Welch correction). VEH = vehicle.
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groups (data not shown), suggesting the absence of an anxiety 
state or alterations in motor activity. In the SI test, 2­way 
ANOVA showed a significant effect of THC treatment only 
(F1–30 = 12.43, p < 0.01). In fact, the time spent in active social 
behaviours was significantly reduced (42%) in animals pre­
treated with THC. With chaetocin coadministration, animals 
showed a milder reduction in social behaviour (27%), which 
did not reach the significance threshold when compared with 
control animals (Fig. 7B). In the FST, 2­way ANOVA showed 
a significant effect of THC treatment only (Fig. 5E and F). 
Adult animals pre­exposed to THC spent more time in immo­
bility (F1–32 = 19.63, p < 0.001) and less time swimming (F1–32 = 
23.96, p < 0.001), suggesting the presence of a passive coping 
strategy. However, these parameters were not prevented by 
chaetocin coadministration (Fig. 7C and 7D).
Discussion
The present study shows that adolescent THC exposure in fe­
male rats induces alterations in specific histone modifications 
in the PFC, with complex kinetics entailing a first round of 
global increased trimethylation of H3K9, followed by a wave 
of histone H3 acetylation with an opposite outcome at the 
transcriptional level. Interestingly, alterations in both histone 
modifications and gene expression were more intense and 
long­lasting following adolescent THC treatment compared 
with adult treatment (a further graphical representation of 
our results is summarized in Fig. 8 and Fig. 9). This differen­
tial effect clearly indicates age­dependency in THC­induced 
molecular alterations, at least in the PFC, shedding new light 
on molecular mechanisms underlying adolescent susceptibil­
ity to substance­induced psychopathologies. The PFC is 
mostly involved in the modulation of cognitive and emo­
tional behaviour through top–down inhibition of subcortical 
affective circuitry,36,37 playing an important role in the onset 
of  cannabis­induced neuropsychiatric disorders.38 Notably, 
THC­induced epigenetic changes impact the expression of a 
set of genes associated with plasticity, likely contributing to 
circuitry maladaptation instrumental to disease pathogenesis. 
These changes include genes encoding some elements of the 
cAMP transduction pathways together with Homer1, Pick1, 
Pdyn and Reln. However, we cannot exclude that gene re­
pression mediated by THC could also involve other genes 
that are not associated with neuronal plasticity. Moreover, 
H3K9me3 increases 24 hours after THC treatment, and this 
modification is likely mediated by the upregulation of 
Fig. 5: H3K9me3 levels at specific gene promotor bodies measured by chromatin immunoprecipitation–qualitative poly-
merase chain reaction 24 hours after the end of Δ9-tetrahydrocannabinol (THC) treatment. Values are displayed as fold en-
richment over the input samples. Data are expressed as means ± standard errors of the mean for 10 animals per experimen-
tal group. *p < 0.05 compared with controls (Student t test with Welch correction). VEH = vehicle.
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Suv39H1, a histone methyltransferase specifically involved in 
the trimethylation of H3K9. Meanwhile, transcription of 
 selected genes associated with plasticity is silenced, which is 
in line with the development of cognitive impairments later 
in life. Indeed, the pharmacological inhibition of specific 
HMTs and consequent H3K9me3 normalization during THC 
treatment is able to prevent the onset of THC­ mediated cog­
nitive deficits in adulthood.
The enhanced histone H3 acetylation observed from 24 to 
48 hours after THC treatment may represent either a direct 
Fig. 6: (A) Effect of adult Δ9-tetrahydrocannabinol (THC) exposure on histone modification 2, 24 and 48 hours after the last THC 
injection. Data are expressed as means ± standard errors of the mean (SEM) for at least 4 animals per experimental group. *p < 
0.05 compared with controls (Student t test with Welch correction). (B) Effect of adult THC exposure on the expression of genes 
closely associated with the endocannabinoid system or synaptic plasticity 24 hours after the last THC injection. Data are ex-
pressed as log2 ± SEM for 4 animals per experimental group. *p < 0.05 compared wtih controls (Student t test with Welch cor-
rection). VEH = vehicle.
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effect of THC, displaying a delayed onset compared with 
THC­mediated H3K9me3 increase, or the result of a homeo­
static response directly induced by the aberrant increase of 
SUV39H1 and consequent H3K9me3 accumulation. In both 
cases, active histone H3 acetylation should represent an epi­
genetic mechanism that counteracts the strong transcriptional 
repression mediated by SUV39H1 overexpression. Indeed, 
48 hours after the end of THC treatment, when H3K9 acetyla­
tion is promoted, a strong transcriptional reactivation of 
those same genes that were repressed at 24 hours occurs. 
Strikingly, 8 of these genes have altered expression at 
75 PND and appear to be particularly important for the 
 depressive/psychotic­like phenotype described in THC­ 
exposed animals. Among these genes, Grm3, Gabra, Abat and 
Dlg4 are components of the glutamatergic and GABAergic 
systems and have been shown to play a relevant role in the 
pathophysiology of schizophrenia and mood disorders.39–43 
Moreover, 2 other genes whose THC­mediated deregulation 
during adolescence persisted at 75 PND, Gria1 and Reln, have 
also been found to be modified in postmortem studies per­
formed in the cortex of patients with schizophrenia.44–47 Thus, 
the 2 main THC­induced epigenetic events, the early (0–24 h) 
H3K9me3 upregulation followed by a delayed (24–48 h) in­
crease of H3 acetylation, dramatically change the physiologic 
Table 1: Genes downregulated by Δ9-tetrahydrocannabinol and prevented by chaetocin coadministration
Condition; mean ± SEM (n) THC × chaetocin interaction
Gene Vehicle Chaetocin THC THC + chaetocin F p value*
Cnr1 0.000 ± 0.080 (11) 0.515 ± 0.179 (5) –0.652 ± 0.148 (10) 0.954 ± 0.174 (7) F1–29 = 14.1 < 0.001
Mgll 0.000 ± 0.138 (11) 0.059 ± 0.227 (5) –0.720 ± 0.083 (11) 0.469 ± 0.192 (7) F1–30 = 13.43 < 0.001
Gria1 0.000 ± 0.110 (11) –0.056 ± 0.248 (5) –0.734 ± 0.124 (10) 0.161 ± 0.122 (7) F1–29 = 10.72 0.003
Grin2a 0.000 ± 0.101 (12) –0.304 ± 0.093 (5) –0.346 ± 0.116 (14) 0.393 ± 0.187 (7) F1–33 = 11.23 0.002
Grin2b 0.000 ± 0.074 (11) –0.474 ± 0.123 (5) –0.682 ± 0.115 (13) –0.086 ± 0.172 (7) F1–32 = 17.04 < 0001
Grm2 0.000 ± 0.175 (9) –0.337 ± 0.157 (5) –0.951 ± 0.196 (11) 0.211 ± 0.267 (7) F1–28 = 11.63 0.002
Grm3 0.000 ± 0.076 (9) –0.050 ± 0.102 (5) –0.395 ± 0.084 (12) 0.401 ± 0.272 (7) F1–28 = 7.21 0.012
Grm5 0.000 ± 0.085 (10) 0.386 ± 0.158 (5) –0.573 ± 0.129 (12) 0.999 ± 0.212 (7) F1–30 = 15.32 < 0.001
Gabbr1 0.000 ± 0.141 (11) 0.050 ± 0.255 (5) –0.657 ± 0.095 (11) 0.336 ± 0.280 (6) F1–29 = 6.88 0.010
Gabra2 0.000 ± 0.102 (11) 0.144 ± 0.173 (5) –0.349 ± 0.109 (13) 0.217 ± 0.254 (7) F1–31 = 5.56 0.025
Gad1 0.000 ± 0.151 (11) –0.403 ± 0.111 (4) –0.640 ± 0.082 (14) –0.360 ± 0.425 (7) F1–32 = 12.09 0.001
Bdnf 0.000 ± 0.104 (11) 0.438 ± 0.213 (5) –0.465 ± 0.148 (10) 1.349 ± 0.234 (6) F1–28 = 7.84 < 0.001
Dlg4 0.000 ± 0.528 (12) 0.018 ± 0.209 (5) –1.855 ± 0.376 (14) 0.755 ± 0.195 (7) F1–34 = 7.07 0.010
Prkaca 0.000 ± 0.052 (12) 0.171 ± 0.177 (5) –0.593 ± 0.085 (12) 0.477 ± 0.348 (7) F1–32 = 7.21 0.010
Nos1 0.000 ± 0.113 (10) –0.114 ± 0.103 (5) –0.332 ± 0.101 (13) 0.886 ± 0.757 (7) F1–29 = 5.56 0.030
Creb1 0.000 ± 0.099 (11) –0.356 ± 0.181 (5) –0.310 ± 0.103 (14) 0.147 ± 0.191 (7) F1–31 = 17.35 < 0.001
Homer1 0.000 ± 0.123 (11) –0.267 ± 0.183 (5) –0.928 ± 0.073 (11) 0.194 ± 0.149 (7) F1–30 = 28.56 < 0.001
Crebbp 0.000 ± 0.119 (10) –0.450 ± 0.189 (5) –0.676 ± 0.131 (14) 0.135 ± 0.195 (7) F1–32 = 14.78 < 0.001
Reln 0.000 ± 0.119 (10) 0.129 ± 0.108 (4) –0.894 ± 0.226 (12) –0.210 ± 0.251 (7) F1–29 = 23.33 < 0.001
SEM = standard error of the mean; THC = Δ9-tetrahydrocannabinol. 
*THC + chaetocin v. THC; 2-way analysis of variance followed by Tukey multiple comparison test.
Table 2: Genes downregulated by Δ9-tetrahydrocannabinol and not prevented by chaetocin coadministration
Condition; mean ± SEM (n) THC × chaetocin interaction
Gene Vehicle Chaetocin THC THC + chaetocin F p value*
Gria2 0.000 ± 0.074 (10) 0.164 ± 0.133 (5) –0.254 ± 0.050 (10) 0.322 ± 0.160 (7) F1–27 = 2.68 0.11
Gabbr2 0.000 ± 0.099 (11) 0.032 ± 0.157 (5) –0.567 ± 0.079 (11) 0.070 ± 0.373 (7) F1–30 = 2.60 0.12
Abat 0.000 ± 0.227 (8) –1.173 ± 0.398 (4) –1.158 ± 0.183 (11) –1.253 ± 0.402 (7) F1–25 = 3.36 0.07
Htr2a 0.000 ± 0.273 (10) –0.567 ± 0.128 (4) –0.949 ± 0.175 (12) –1.023 ± 0.314 (7) F1–29 = 0.81 0.37
Sirt1 0.000 ± 0.135 (10) –0.503 ± 0.179 (5) –0.523 ± 0.130 (13) –0.356 ± 0.232 (6) F1–30 = 3.80 0.06
Pick1 0.000 ± 0.119 (9) –0.370 ± 0.232 (5) –1.121 ± 0.212 (12) –0.614 ± 0.227 (6) F1–28 = 4.00 0.06
Pdyn 0.000 ± 0.145 (11) –0.191 ± 0.126 (4) –0.541 ± 0.086 (13) –0.211 ± 0.258 (6) F1–30 = 2.46 0.13
Synpo 0.000 ± 0.052 (11) 0.133 ± 0.196 (5) –0.429 ± 0.107 (13) –0.267 ± 0.522 (7) F1–31 = 3.92 0.06
Arc 0.000 ± 0.229 (12) –0.529 ± 0.632 (5) –0.870 ± 0.181 (11) 0.318 ± 0.336 (7) F1–30 = 1.08 0.31
Adcy1 0.000 ± 0.135 (11) 0.154 ± 0.300 (4) –1.040 ± 0.163 (14) –0.114 ± 0.239 (7) F1–32 = 3.34 0.08
SEM = standard error of the mean; THC = Δ9-tetrahydrocannabinol. 
*THC + chaetocin v. THC; 2-way analysis of variance.
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expression of the analyzed genes. These genes may play a cru­
cial role in the correct developmental trajectory of the 
 adolescent brain, thus their aberrant expression could affect 
the shaping of adult brain organization. Consistently, these al­
terations in gene expression fluctuations may drive changes in 
the PFC maturational events occurring, for example, at gluta­
matergic and GABAergic synapses after heavy adolescent 
THC exposure, as previously described.10,12 This leads to an 
adult brain characterized by altered functionality likely un­
derpinning cognitive impairments present in the depressive/ 
psychotic­like phenotype observed in female rats after ado­
lescent THC exposure.10,11 Thus, hindering the first event (the 
increase in Suv39H1/H3K9me3) through chaetocin adminis­
tration, we prevented, at least in part, the flow of events that 
lead to impairments in brain and behaviour (Fig. 10).
In support of evidence for major vulnerability of the ado­
lescent brain to the long­lasting adverse effects of canna­
binoids, it is worth commenting on the different results we 
obtained after adult and adolescent THC treatments. Expo­
sure to THC at both ages induced a significant increase in 
H3K9me3 2 hours after the last THC injection. However, at 
the later time points, adult THC exposure did not induce any 
significant alteration. Thus, we can speculate that the increase 
in H3K9me3 is closely associated with THC treatment, re­
gardless of the time of administration, whereas the later his­
tone alterations (H3K9me2, H3K14ac and H3K9ac) represent 
a feature of adolescent exposure.
The different epigenetic response between the adolescent 
and adult brain might play a role in the mechanisms involved 
in the long­term behavioural impairments induced by 
Fig. 7: Effects of chaetocin administration during adolescent Δ9-tetrahydrocannabinol (THC) exposure on adult behaviour 
(postnatal day 75): (A) discrimination index in the novel object recognition test, (B) active social behaviours in the social inter-
action test, (C) immobility and (D) swimming parameters in the forced swim test. Data are expressed as means ± standard 
errors of the mean for at least 5 animals per group. *p < 0.05, **p < 0.01, ***p < 0.001 compared with controls; °°°p < 0.001 
compared with THC-treated animals (2-way analysis of variance followed by Tukey post hoc test). VEH = vehicle.
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Fig. 9: Gene expression following adolescent and adult Δ9-tetrahydrocannabinol (THC) exposure, 24 hours after the last 
THC injection. Twenty-five genes are specifically downregulated after adolescent THC exposure, whereas only 1 gene 
(Ppara) is specifically downregulated after adult THC exposure. The overlap section shows genes downregulated by 
both treatments, except for Bdnf, which is downregulated after adolescent THC exposure but upregulated after adult 
THC exposure.
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 adolescent, but not adult, THC exposure.11 We cannot assess 
whether the different epigenetic/transcriptional response in­
duced by THC administration in adolescent compared with 
adult animals was due to an age­specific THC effect on the 
epigenome or to a differential homeostatic response promoted 
by H3K9me3 upregulation occurring only in young rats.
A picture emerges only in adolescent rats in which transcrip­
tional increase of THC target genes is promoted to counter act 
their early THC­mediated transcriptional repression. How­
ever, this seemingly compensatory mechanism aberrantly trig­
gers a pathologic transcriptional facilitation of a subset of 
genes associated with disease­inherent long­lasting effects, 
 ultimately modifying PFC circuitry with a maladaptive mean.
Furthermore, in the adult rat brain we found upregulation of 
the gene coding for Bdnf, a neurotrophin that regulates synap­
tic function and plasticity in the mature nervous system.48 Re­
cent studies suggest an important protective role of Bdnf in al­
cohol use disorders49 or implicate Bdnf in the medial PFC as a 
negative regulator of cocaine­seeking.50,51 Based on these obser­
vations, we might speculate that the increase in Bdnf mRNA 
levels restricted to adult THC exposure could represent a pro­
tective response. If this is the case, the lack of such adaptation 
after adolescent THC exposure is consistent with the observa­
tion that the adolescent brain is more vulnerable to THC effects.
Impairments in chromatin remodelling enzymes are increas­
ingly being recognized as playing a crucial role in the develop­
ment and maintenance of addictive disorders. The crucial role 
of the HMT G9a was shown in the structural and behavioural 
plasticity induced by cocaine.21 More interestingly, chronic am­
phetamine exposure induced histone H3 methylation (K4 and 
K9) on the c­fos promoter in parallel with the increase in pro­
tein amounts of the HMT Suv39H1.52 Consistently, our direct 
analysis of the histone marker H3K9me3 at selected genes re­
vealed a correlation between THC­ mediated transcriptional 
downregulation and increase of this repressive histone 
marker, strengthening the hypothesis that transcriptional re­
pression is operated at least in part by chromatin structure 
modification at specific genes. However, given the global 
THC­mediated increase of H3K9me3, we should also take into 
consideration the possibility that this modification might occur 
at specific intergenic regions generating heterochromatic do­
mains that might play an indirect effect on gene expression. It 
is therefore possible that the increase of Suv39H1 we observed 
in our study could be a potential mechanism through which 
THC acts on chromatin to induce long­lasting effects. Indeed, 
daily coadministration of THC and chaetocin, an inhibitor of 
the HMTs acting on H3K9,34,35 prevented the increase in 
H3K9me3 as well as the large gene downregulation induced 
Fig. 10: Flow of events induced by adolescent Δ9-tetrahydrocannabinol (THC) exposure and prevented by chaetocin coadministration. PND = 
postnatal day.
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by THC in the PFC. Specifically, chaetocin prevented the re­
pression of 19 of 29 genes, suggesting that their expression 
could be mediated by H3K9me3 levels. Remarkably, these 
genes mainly belong to the ECS and the glutamatergic syn­
apse. It has been suggested that the composition of the ECS 
may be a general feature of most glutamatergic synapses in the 
brain,53 including the PFC.54 Impairments of PFC glutamater­
gic transmission are detrimental to PFC­dependent cognitive 
processes, such as the ones evaluated with the NOR test.55 
Thus, we can speculate that preventing glutamatergic and 
 endocannabinoid downregulation of genes by chaetocin could 
account for the lack of cognitive deficits observed after adoles­
cent THC exposure.
In contrast, the lack of effect of chaetocin on Abat down­
regulation and on downregulation of 9 other genes (Gria2, 
Gabbr2, Sirt1, Pick1, Pdyn, Synpo, Arc, Adcy1 and Htr2a) im­
plies that these genes might be regulated by mechanisms dif­
ferent from H3K9me3. Accordingly, chromatin immunopre­
cipitation results did not detect a significant increase in 
H3K9me3 levels in the Abat gene. At the behavioural level, 
chaetocin administration during adolescent THC exposure 
prevented the development of cognitive deficits in adulthood, 
with only a partial effect, if any, on emotional behaviour. Lack 
of complete behavioural recovery, in particular for the emo­
tional phenotype, could reflect the existence of 2 distinct THC 
downstream pathways: a former, where H3K9me3 upregula­
tion represents the first step of a chain of events, principally 
impacting cognition (Fig. 10), and a latter, independent of in­
creased H3K9me3, more related to affective behaviour. This 
suggests that THC alterations in an emotional behaviour 
pathway could be triggered by other histone modifications, 
such as H3 acetylation, occurring in other brain areas. Further 
studies are warranted to explore whether drugs inhibiting 
these other modifications might hold promise in reverting the 
adverse effects of adolescent cannabinoid exposure. 
Limitations
Our study should be considered together with some limita­
tions. We focused our study only on female rats, and because 
a recent study56 has suggested that the sexes differ in canna­
binoid signalling and thus in response to THC, we cannot ex­
tend these results to male rats. Moreover, our gene expres­
sion analyses were limited to a specific subset of genes 
closely associated with the endocannabinoid system and 
brain plasticity, thus we cannot exclude that other genes may 
be affected by adolescent THC exposure. 
Conclusion
Through a mechanism involving SUV39H1, THC modifies 
histone modifications and, thereby, expression of plasticity 
genes. This pathway appears to be relevant for the develop­
ment of cognitive deficits. To our knowledge, chaetocin has 
been used for the first time as a possible modulator of behav­
ioural traits relevant to psychiatric disorders, thus suggesting 
that H3K9me3 could be considered as a possible target for 
therapeutic interventions.
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